Amylyx PharmaceuticalsAMLX -1.60%33 14-Day RSI is 67.73 as of Jul. 08, 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,048 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks worse than 90.94% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Amylyx Pharmaceuticals 14-Day RSI Related Terms
AMLX vs ANIP, TRLV, PBH: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (AMLX) has a 14-Day RSI of 67.73 as of Jul. 08, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Amylyx Pharmaceuticals and its competitors. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #953 out of 1048 companies in the Drug Manufacturers industry, placing it in the top 90.9%.
Is Amylyx Pharmaceuticals' 14-Day RSI too high?
Amylyx Pharmaceuticals' current 14-Day RSI is 67.73. The Drug Manufacturers industry median 14-Day RSI is 48.91. Amylyx Pharmaceuticals' value of 67.73 is 38.5% above this industry median. Based on the distribution chart, Amylyx Pharmaceuticals ranks #953 out of 1048 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' 14-Day RSI compare to ANIP and TRLV?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #953 out of 1048 companies for 14-Day RSI. This places Amylyx Pharmaceuticals in the lower half of its industry. The industry median 14-Day RSI is 48.91. Amylyx Pharmaceuticals' value of 67.73 is 38.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 48.91, based on 1,048 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amylyx Pharmaceuticals's current 14-Day RSI of 67.73 is 38.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 48.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current 14-Day RSI is 67.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current 14-Day RSI of 67.73. The current 14-Day RSI is 67.73 and 38.5% above the Drug Manufacturers industry median of 48.91. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current 14-Day RSI is 67.73 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 